Figure 28 depicts a chart of Odds ratio of myelotoxicity during thiopurine treatment of chronic autoimmune disease, heterozygotes versus noncarriers. The results are odds ratio of 0.77 with a confidence interval of 95 percent (0.22, 2.65) favoring noncarriers.

Figure 28Odds ratio of myelotoxicity during thiopurine treatment of chronic autoimmune disease, heterozygotes versus noncarriers

From: 3, Results

Cover of Assessment of Thiopurine Methyltransferase Activity in Patients Prescribed Azathioprine or Other Thiopurine-Based Drugs
Assessment of Thiopurine Methyltransferase Activity in Patients Prescribed Azathioprine or Other Thiopurine-Based Drugs.
Evidence Reports/Technology Assessments, No. 196.
Booth RA, Ansari MT, Tricco AC, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.